Collagen Cross Linking

Our practice offers collagen cross linking for conditions such as keratoconus or post-refractive surgery ectasia. Collagen cross linking can also be used in select cases of corneal infection that are not responsive to conventional medications. Collagen cross linking is an FDA approved procedure in the United States. The proposed treatment was first described in 1992.

Keratoconus and post-refractive surgery ectasia are conditions in which the cornea (front part of the eye) is weakened and thinning. This can result in bulging, which can distort vision and lead to corneal scarring. 

Collagen cross linking is something the body naturally does as part of the aging process; it helps to strengthen collagen fibers in the cornea. The collagen cross linking treatment helps to accelerate this process in weakened and thinning corneas. 

During the procedure, we will first remove the front layer of the cornea (the epithelium). A UV light is then shined on the eye for thirty minutes, during which riboflavin (vitamin B2) eye drops are put into the eye every two minutes. Afterwards, a bandage contact lens is placed to help the surface heal. Follow-up visits will be scheduled after the procedure, to compare visual acuity and progression pre- and post-treatment. For many, this procedure may delay or prevent the need for a corneal transplant.

The information contained within these pages is intended for informational purposes only and does not take the place of consulting a physician.
Created by and for New York Cornea, with offices at Columbia University Medical Center and in Scarsdale, New York.
Caring for your corneas since 1988.